Challenge

LPS (Lipopolysaccharides) is a highly toxic endotoxin found in Gram-negative bacteria, causing severe diseases in both animals and humans. Current diagnostic tests often miss diseases caused by LPS, leading to undetected infections despite visible symptoms. Traditional tests that detect pathogens in milk or blood often return negative results, as LPS—rather than the bacteria itself—is the primary cause of disease. This makes accurate diagnosis difficult.

In 2022, Koru Biotech made a groundbreaking discovery: the identification of a novel LPS biomarker that has the potential to transform diagnostics and treatment for diseases caused by Gram-negative bacteria.

Existing solutions are slow and non-specific, often leading to the overuse of broad-spectrum antibiotics, raising concerns about treatment failure, antibiotic resistance, and delayed cure. Koru Biotech’s discovery addresses these issues head-on, offering a more accurate and rapid detection method that will improve patient outcomes and help mitigate the rise of antimicrobial resistance.